JP2022526367A5 - - Google Patents

Info

Publication number
JP2022526367A5
JP2022526367A5 JP2021557778A JP2021557778A JP2022526367A5 JP 2022526367 A5 JP2022526367 A5 JP 2022526367A5 JP 2021557778 A JP2021557778 A JP 2021557778A JP 2021557778 A JP2021557778 A JP 2021557778A JP 2022526367 A5 JP2022526367 A5 JP 2022526367A5
Authority
JP
Japan
Prior art keywords
approximately
lipocalin
pharmaceutical product
product according
mutheine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021557778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526367A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/058637 external-priority patent/WO2020201038A1/en
Publication of JP2022526367A publication Critical patent/JP2022526367A/ja
Publication of JP2022526367A5 publication Critical patent/JP2022526367A5/ja
Withdrawn legal-status Critical Current

Links

JP2021557778A 2019-03-29 2020-03-27 リポカリンムテインの吸入投与 Withdrawn JP2022526367A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962826767P 2019-03-29 2019-03-29
US62/826,767 2019-03-29
EP19166435 2019-04-01
EP19166435.8 2019-04-01
EP19175818 2019-05-22
EP19175818.4 2019-05-22
EP19177568 2019-05-31
EP19177568.3 2019-05-31
EP19211404 2019-11-26
EP19211404.9 2019-11-26
PCT/EP2020/058637 WO2020201038A1 (en) 2019-03-29 2020-03-27 Inhaled administration of lipocalin muteins

Publications (2)

Publication Number Publication Date
JP2022526367A JP2022526367A (ja) 2022-05-24
JP2022526367A5 true JP2022526367A5 (enExample) 2023-04-03

Family

ID=70292935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557778A Withdrawn JP2022526367A (ja) 2019-03-29 2020-03-27 リポカリンムテインの吸入投与

Country Status (8)

Country Link
US (1) US20220168387A1 (enExample)
EP (1) EP3946417A1 (enExample)
JP (1) JP2022526367A (enExample)
KR (1) KR20210146999A (enExample)
CN (1) CN113939307A (enExample)
AU (1) AU2020253034A1 (enExample)
CA (1) CA3127973A1 (enExample)
WO (1) WO2020201038A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
MX2023007174A (es) * 2020-12-18 2023-09-08 Astrazeneca Ab Formulacion de polvo seco de muteina de lipocalina para el tratamiento del asma.

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7892827B2 (en) * 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
DE602007009995D1 (de) 2006-08-01 2010-12-02 Pieris Ag Muteine von tearlipocalin und verfahren zu deren gewinnung
EP2245054B1 (en) 2008-01-30 2018-11-28 Pieris Pharmaceuticals GmbH Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same
BR112012013662B1 (pt) * 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
AU2011263786B2 (en) * 2010-06-08 2014-11-13 Astrazeneca Ab Tear lipocalin muteins binding IL-4 R alpha
AU2011290751B2 (en) 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
CA2817779C (en) 2010-11-15 2019-02-19 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
US9221885B2 (en) * 2010-12-02 2015-12-29 Pieris Ag Muteins of human lipocalin 2 with affinity for CTLA-4
DK2791684T3 (da) * 2011-12-12 2017-11-27 Pieris Pharmaceuticals Gmbh Fremgangsmåder til forebyggelse eller behandling af forstyrrelser ved forøgelse af biotilgængeligheden af jern og relateret farmaceutisk formulering
EP3453400B1 (en) * 2011-12-13 2021-01-20 Pieris Pharmaceuticals GmbH Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
AP2014007792A0 (en) * 2012-01-09 2014-07-31 Pieris Ag Methods for preventing, treating or diagnosing disorders
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
EP2920202B1 (en) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
WO2014140210A1 (en) * 2013-03-14 2014-09-18 Pieris Ag Novel binding proteins for pcsk9
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
EP3145945B1 (en) 2014-05-22 2020-07-15 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
SG11201705278QA (en) * 2015-01-28 2017-07-28 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
EP3259282A1 (en) 2015-02-18 2017-12-27 Sanofi Novel proteins specific for pyoverdine and pyochelin
PH12017501583B1 (en) * 2015-05-04 2023-01-20 Pieris Pharmaceuticals Gmbh Novel proteins specific for cd137
RU2727165C2 (ru) * 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
DK3298030T5 (en) * 2015-05-18 2024-10-07 Pieris Pharmaceuticals Gmbh Anti-cancerfusionspolypeptid
EP3298029A1 (en) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
EP3115371A1 (en) * 2015-07-07 2017-01-11 Sanofi Fusion molecules
MX2018000447A (es) * 2015-07-15 2018-08-15 Pieris Pharmaceuticals Gmbh Novedosas proteinas especificas para lag-3.
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
JP7225116B2 (ja) * 2017-01-18 2023-02-20 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン
RS64343B9 (sr) * 2018-07-31 2023-11-30 Pieris Pharmaceuticals Gmbh Novi fuzioni protein specifičan za cd137 i pd-l1
AU2019328632A1 (en) * 2018-08-27 2021-03-25 Pieris Pharmaceuticals Gmbh Combination therapies comprising CD137/HER2 bispecific agents and PD-1 axis inhibitors and uses thereof
JP7476219B2 (ja) * 2019-02-26 2024-04-30 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
EP3946415A1 (en) * 2019-03-29 2022-02-09 Astrazeneca AB Lipocalin mutein for treatment of asthma
CA3177098A1 (en) * 2020-06-05 2021-12-09 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1bb
EP4213946A1 (en) * 2020-09-18 2023-07-26 Pieris Pharmaceuticals GmbH Biomarker methods and uses

Similar Documents

Publication Publication Date Title
CN102325532B (zh) 用于减轻肺部炎症的左氧氟沙星吸入剂
JP2021193091A (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
US6297227B1 (en) Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
AU2007298814B2 (en) Galenic form for the trans-mucosal delivery of active ingredients
TW470647B (en) Composition and pharmaceutical combination kit comprising formoterol and budesonide
JP2774379B2 (ja) 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途
JPH0648958A (ja) 吸入による非ステロイド系抗炎症剤の抗反応抗喘息活性
JP2012522009A (ja) 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
EP3678649B1 (en) Intranasal epinephrine formulations and methods for the treatment of disease
KR20110045004A (ko) 충혈제거제 및 코르티코스테로이드를 포함하는 비강내 조성물
WO2018017434A1 (en) Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
ME01494B (me) Farmaceutska formulacija za liječenje gornjeg digestivnog trakta
JP2008110991A (ja) 処置方法
Gümrü et al. Oral candidiasis as a local adverse effect of inhaled corticosteroids: what the dental practitioner should know
JP2003040797A (ja) 抗炎症性肺疾患およびａｒｄｓにおける抗トロンビン吸入のための医薬製剤
AU2013384129B2 (en) Oral suspension for treating eosinophilic esophagitis
JP2003513048A (ja) 気道狭窄の治療のための酸化窒素の使用
WO2015009776A1 (en) Low dose corticosteroid microemulsion compositions and methods of treatments thereof
JP5220741B2 (ja) アンドラスト／グルココルチコイドの併用
HK40121592A (en) Intranasal epinephrine formulations and methods for the treatment of disease
Mason American Thoracic Society 2019 International Conference. Dallas, Texas, USA-May 17-22, 2019
DE102024001175A1 (de) Zubereitung zur Behandlung von entzündlichen Erkrankungen der Atemwege.
WO2021211854A1 (en) Inhalable formulation of a solution containing tiotropium bromide
WO2022005321A1 (en) Inhaled tocilizumab for treating interleukin-6 related respiratory diseases
US20200046638A1 (en) Pharmaceutical composition for the treatment of sinusitis and copd